What It Is
LL-37 is not a synthetic laboratory invention. It is a naturally occurring human peptide, produced by cleaving a larger precursor protein called hCAP-18, which is encoded by the CAMP gene.[1] Neutrophils, skin cells, and other epithelial tissue produce it as part of the body's innate immune system, making LL-37 fundamentally different from engineered growth-hormone-style research peptides.
Its name reflects its structure: it begins with two leucines and contains 37 amino acids total.[2] LL-37 folds into an amphipathic alpha-helix, with one face attracted to fats and the other to water, a shape that helps it interact with microbial cell membranes and immune cells.
How It Works
LL-37 works through more than one mechanism. Its positive charge lets it bind to the negatively charged membranes of many bacteria and, in laboratory conditions, disrupt them — the basis for calling it an antimicrobial peptide.[4] It also acts as a chemoattractant that draws immune cells such as neutrophils, monocytes, and T cells toward a site of injury or infection,[6] and it interacts with Toll-like receptors by binding molecules such as bacterial DNA, RNA, and lipopolysaccharide.[15]
This last interaction can either calm or intensify inflammatory signaling depending on the tissue and context. LL-37 is therefore not simply "anti-inflammatory" or "pro-inflammatory" — its effect shifts with concentration, tissue, and the specific immune pathway involved.
What the Research Shows
LL-37's role in normal human biology is well established: it is a documented, naturally produced component of innate immunity at skin, airway, and gut surfaces.[3] Laboratory studies show activity against a range of bacteria, fungi, and some viruses under controlled conditions, though lab activity does not automatically predict effectiveness in a real infection.[5]
Human clinical evidence is limited but not absent. A randomized, placebo-controlled trial tested topical LL-37 at 0.5 mg/mL and 1.6 mg/mL in patients with hard-to-heal venous leg ulcers and reported improved wound healing with acceptable tolerability.[7] That is a genuine, if narrow, positive human signal — but it is a single trial in one wound type using one topical formulation, not evidence supporting broader antimicrobial, immune, or dermatologic use.
Safety & Side Effects
The venous leg ulcer trial provides some reassuring tolerability data for topical use in that specific setting, but it does not establish a safety profile for LL-37 given by other routes, at other doses, or in other populations.[7] Outside that trial, there is no standardized adverse-event profile of the kind an approved drug label would provide.
Notable safety considerations include:
- LL-37 has been shown to form complexes with the body's own DNA and RNA that can trigger inflammatory signaling implicated in psoriasis, meaning it can worsen certain autoimmune or inflammatory skin conditions rather than only calm them[16][17]
- Local irritation or hypersensitivity is plausible given its direct interaction with skin and immune cells
- Its mixed, sometimes tumor-promoting behavior in cancer research means people with a cancer history should treat any LL-37 exposure with particular caution
- Unapproved or research-only products carry the usual added risks of impurity, incorrect labeling, and inconsistent dosing
Regulatory Status
Despite being a natural human peptide with real clinical trial data behind it, LL-37 has no FDA-approved standalone drug product; it does not appear with approved prescribing information in Drugs@FDA or DailyMed.[9][10] It also does not appear to hold an EMA-authorized medicinal product status in Europe.[13]
Registration on ClinicalTrials.gov for LL-37-related studies exists, but trial registration is not equivalent to regulatory approval.[21] LL-37 should be regarded as an investigational compound for therapeutic purposes; any commercially available LL-37 product is a research or compounded item rather than an approved medicine, and it does not carry the manufacturing or quality oversight that approval would require.
Cancer Research Context
LL-37's relationship to cancer is one of the more nuanced parts of its research record. Depending on cancer type, receptor pathways, and experimental model, studies have reported LL-37 promoting tumor cell growth and migration in some contexts while showing inhibitory or immune-modulating effects in others.[8] This reflects how context-dependent immune-active peptides can behave, rather than a contradiction in the data.
None of this research establishes LL-37 as a cancer treatment. It is cancer biology research, and any therapeutic application would require dedicated clinical trials that do not currently exist.